Elusys' Anthim Dramatically Improves Survival Of Animals Treated After Active Anthrax Infection

Elusys Therapeutics, Inc. (Elusys), a privately-held biopharmaceutical company developing antibody-based therapies for the treatment of life-threatening infectious diseases, today announced pivotal animal efficacy results of AnthimTM, a high-affinity humanized and deimmunized monoclonal antibody targeting the anthrax toxin protective antigen.

http://www.medicalnewstoday.com/articles/104984.php